Arrowhead Pharmaceuticals
(NASDAQ) ARWR
Arrowhead Pharmaceuticals Financials at a Glance
Market Cap
$8.09B
Revenue (TTM)
$1.09B
Net Income (TTM)
$202.26M
EPS (TTM)
$1.54
P/E Ratio
37.56
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Price
$57.73
Volume
77,291
Open
$60.71
Price
$57.73
Volume
77,291
Open
$60.71
Previous Close
$57.73
Daily Range
$57.61 - $61.37
52-Week Range
$9.57 - $76.76
Dividend
$0.00
Beta (Volatility)
1.63 (High)
Price
$57.73
Volume
77,291
Open
$60.71
Previous Close
$57.73
Daily Range
$57.61 - $61.37
52-Week Range
$9.57 - $76.76
ARWR News
ARWR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Arrowhead Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
711
CEO
Christopher Richard Anzalone, PhD
Website
www.arrowheadpharma.comHeadquarters
Pasadena, CA 91105, US
ARWR Financials
Key Financial Metrics (TTM)
Gross Margin
99%
Operating Margin
28%
Net Income Margin
19%
Return on Equity
65%
Return on Capital
24%
Return on Assets
13%
Earnings Yield
2.66%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.09B
Shares Outstanding
140.03M
Volume
77.29K
Short Interest
0.00%
Avg. Volume
2.94M
Financials (TTM)
Gross Profit
$805.52M
Operating Income
$98.35M
EBITDA
$164.82M
Operating Cash Flow
$179.55M
Capital Expenditure
$22.67M
Free Cash Flow
$156.89M
Cash & ST Invst.
$919.37M
Total Debt
$366.28M
Arrowhead Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$264.03M
+10461.3%
Gross Profit
$264.03M
+10461.3%
Gross Margin
100.00%
N/A
Market Cap
$8.09B
N/A
Market Cap/Employee
$13.29M
N/A
Employees
609
N/A
Net Income
$30.81M
+117.8%
EBITDA
$57.17M
+138.6%
Quarterly Fundamentals
Net Cash
$603.84M
+289.2%
Accounts Receivable
$218.87M
+8654.8%
Inventory
$0.00
N/A
Long Term Debt
$265.24M
-69.3%
Short Term Debt
$47.53M
+480.7%
Return on Assets
12.61%
N/A
Return on Invested Capital
23.92%
N/A
Free Cash Flow
$11.33M
+107.4%
Operating Cash Flow
$13.48M
+109.2%